Valuation: Agenus Inc.

Market Cap 120M 105M 96.93M 90.75M 170M 11.31B 174M 1.17B 451M 5.59B 450M 441M 19.39B P/E 2026 *
3.67x
P/E 2027 * -16x
Enterprise Value 120M 105M 96.93M 90.75M 170M 11.31B 174M 1.17B 451M 5.59B 450M 441M 19.39B EV / Sales 2026 *
0.65x
EV / Sales 2027 * 0.91x
Free-Float
93.3%
Yield 2026 *
-
Yield 2027 * -
05-22 Agenus Inc Presents Phase 2 Botensilimab Plus Balstilimab Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma CI
05-22 Agenus and Noetik Present Asco 2026 Data Linking Ai Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with Bot+Bal in Mss Metastatic Crc CI
05-16 Agenus Inc Announces Publication Of Phase 1b Botensilimab And Balstilimab Data In Post-Immunotherapy Hepatocellular Carcinoma CI
05-16 Agenus Inc. Announces Resignation of Austin Charette as Principal Accounting Officer, Effective May 29, 2026 CI
05-12 Agenus Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
05-11 Agenus reports first quarter 2026 financial results and highlights BOT+BAL execution across global access and Phase 3 development RE
04-28 Biodlink International Company Limited Announces Changes in Executives and Board Committee, Effective from 29 April 2026 CI
04-21 Agenus Names BAP Pharma as Global Partner for Botensilimab Plus Balstilimab Access Programs MT
04-21 Agenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026 CI
04-21 Agenus Inc Names BAP Pharma As Exclusive Global Partner For Botensilimab Plus Balstilimab Access Programs CI
04-18 Agenus reports phase II data demonstrating immune reprogramming and durable survival with botensilimab, balstilimab and agent-797 in PD-1 refractory gastroesophageal cancer RE
04-18 Agenus Inc Announces Phase II Data For Botensilimab, Balstilimab and AgenT-797 In Pd-1 Refractory Gastroesophageal Cancer CI
04-01 Agenus Inc Announces First Patient Enrolled In Global Phase 3 BATTMAN Trial Of BOT Plus BAL Immunotherapy Combination In MSS Or PMMR Metastatic Colorectal Cancer CI
1 day+5.03%
1 week-0.49%
Current month-13.57%
1 month-8.89%
3 months-12.06%
6 months-8.61%
Current year-3.66%
1 week 2.85
Extreme 2.85
3.18
1 month 2.85
Extreme 2.85
3.53
Current year 2.71
Extreme 2.71
5.08
1 year 2.71
Extreme 2.71
7.34
3 years 1.38
Extreme 1.38
38.6
5 years 1.38
Extreme 1.38
135.8
10 years 1.38
Extreme 1.38
149.8
Manager TitleAgeSince
Chief Executive Officer 72 31/03/1994
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - 01/11/2021
Director TitleAgeSince
Chairman 72 04/11/2010
Director/Board Member 68 08/03/2007
Director/Board Member 68 07/12/2006
Date Insider Type Main position Quantity % Market Cap.
06-12Free

Chief Executive Officer

4,925 0.0118%
05-29Free

Chief Executive Officer

4,644 0.0112%
05-15Free

Chief Executive Officer

4,540 0.0118%
Change 5-day change 1-year change 3-year change Capi.($)
+5.03%-0.49%-38.39%-90.78% 120M
-0.48%+7.20%-5.08%+2.45% 46.36B
+0.45%+7.74%+376.63%+618.31% 37.88B
+1.76%+13.42%+20.34%-10.99% 31.12B
+0.34%+2.01%+8.94%+53.95% 30.61B
-4.16%-4.44%+8.53%+16.06% 24.69B
-1.48%+12.95% - - 16.25B
+0.48%+15.33%+71.29%+133.45% 14.85B
+1.00%+10.30%+13.31%+22.84% 13.58B
+2.03%+5.69%+101.63%+105.14% 12.95B
Average +0.48%+6.93%+61.91%+94.49% 22.84B
Weighted average by Cap. -0.13%+7.66%+83.42%+136.14%

Financials

2026 *2027 *
Net sales 185M 162M 149M 140M 262M 17.42B 268M 1.79B 694M 8.61B 694M 678M 29.86B 131M 115M 106M 99.46M 187M 12.4B 190M 1.28B 494M 6.13B 494M 483M 21.25B
Net income 46M 40.33M 37.18M 34.81M 65.27M 4.34B 66.62M 447M 173M 2.14B 173M 169M 7.44B -9.9M -8.68M -8M -7.49M -14.05M -934M -14.34M -96.17M -37.21M -462M -37.17M -36.36M -1.6B
Net Debt - -
Logo Agenus Inc.
Agenus Inc. is an immuno-oncology (I-O) company targeting cancer with a comprehensive pipeline of immunological agents. The company is focused on expanding patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Its I-O portfolio is driven by several platforms and programs, which include multiple antibody discovery platforms, antibody candidate programs, its saponin-based vaccine adjuvant platform, and a pipeline of novel allogeneic invariant natural killer T cell (iNKT) therapies for treating cancer and other immune-mediated diseases, controlled by MiNK. Its antibody candidate programs include botensilimab (BOT) and balstilimab (BAL) (a PD-1 blocking antibody). The Company has secured committed manufacturing capacity to support BOT+BAL supply needs for its clinical trials, global access programs and future commercialization.
Employees
81
Date Price Change Volume
26/06/26 $3.020 +4.86% 363,908
25/06/26 $2.880 -1.37% 594,632
24/06/26 $2.920 -4.89% 625,201
23/06/26 $3.070 +0.99% 438,569
22/06/26 $3.040 +1.33% 476,300
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.880USD
Average target price
15.50USD
Spread / Average Target
+438.19%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AGEN Stock